Type
Internal restructuring
Country
France
Region
Sud-Ouest; Aquitaine; Gironde
Location of affected unit(s)
Martillac
Sector
Manufacturing
Manufacture of chemicals and pharmaceuticals
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.20 - Manufacture of pharmaceutical preparations

109 jobs
Number of planned job losses
Job loss
Announcement Date
17 January 2025
Employment effect (start)
17 January 2025
Foreseen end date

Description

The German multinational Merck is restructuring, cutting 109 jobs from two of its subsidiaries in Martillac. Thirty job cuts on a voluntary basis will occur in its Life Science branch, which produces pharmaceuticals. Life Science will be sold to the American company AbbVie, transferring 300 jobs (the acquisition is not linked to the job cuts). Additionally, the subsidiary Healthcare, which produces pharmaceuticals to treat a range of diseases such as cancer, will cut 79 jobs. This is due to a client's decision to internalize production, thereby forcing the factory to close by mid-2026. In 2021, the company had invested 175 million euros and had hired 150 workers over the past few years.

Merck had a total of 400 employees in Martillac. Several large restructurings have been recorded on the ERM database, with the latest in France hiring 350 jobs in 2021 Merck 2021 - FR.


Sources

Citation

Eurofound (2025), Merck, Internal restructuring in France, factsheet number 202227, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/202227.